Gall Matthew bought KLRS
November 3, 2025 · Form 4 insider transaction
Gall Matthew bought 235,000 shares of Kalaris Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
235,000
Price
$0.00
Total value
N/A
InsiderGall Matthew
RoleOfficer
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateNovember 3, 2025
Filing dateNovember 3, 2025
Shares owned after235,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.